MX392158B - Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). - Google Patents

Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).

Info

Publication number
MX392158B
MX392158B MX2017012397A MX2017012397A MX392158B MX 392158 B MX392158 B MX 392158B MX 2017012397 A MX2017012397 A MX 2017012397A MX 2017012397 A MX2017012397 A MX 2017012397A MX 392158 B MX392158 B MX 392158B
Authority
MX
Mexico
Prior art keywords
ache
recognizes
peptide
antibody
acetylcholinesterase enzyme
Prior art date
Application number
MX2017012397A
Other languages
English (en)
Spanish (es)
Other versions
MX2017012397A (es
Inventor
Paul Morrill
Sara Garcia-Rates
Susan Greenfield
Original Assignee
Neuro Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Bio Ltd filed Critical Neuro Bio Ltd
Publication of MX2017012397A publication Critical patent/MX2017012397A/es
Publication of MX392158B publication Critical patent/MX392158B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
MX2017012397A 2015-03-27 2016-03-23 Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). MX392158B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1600871.6A GB2541477A (en) 2015-03-27 2016-01-18 Antibody
PCT/GB2016/050804 WO2016156803A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache

Publications (2)

Publication Number Publication Date
MX2017012397A MX2017012397A (es) 2018-01-26
MX392158B true MX392158B (es) 2025-03-21

Family

ID=53178191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012397A MX392158B (es) 2015-03-27 2016-03-23 Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).

Country Status (13)

Country Link
US (1) US10954306B2 (enExample)
EP (1) EP3274371B1 (enExample)
JP (1) JP7327897B2 (enExample)
KR (1) KR102626626B1 (enExample)
CN (1) CN107531796A (enExample)
AU (1) AU2016240020B2 (enExample)
BR (1) BR112017020769A2 (enExample)
CA (1) CA2979972A1 (enExample)
ES (1) ES2952723T3 (enExample)
GB (2) GB201505239D0 (enExample)
MX (1) MX392158B (enExample)
RU (1) RU2729491C2 (enExample)
WO (1) WO2016156803A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
GB202112831D0 (en) * 2021-09-09 2021-10-27 Neuro Bio Ltd Biomarker
GB202113941D0 (en) 2021-09-29 2021-11-10 Neuro Bio Ltd Skin biomarker
WO2024052650A1 (en) 2022-09-08 2024-03-14 Neuro-Bio Ltd Lateral flow device for diagnosing alzheimer's disease using the t14 peptide
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease
GB202308779D0 (en) * 2023-06-13 2023-07-26 Neuro Bio Ltd Aptamer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
US20040038875A1 (en) * 2000-03-29 2004-02-26 Greenfield Susan Adele Alpha 7nicotinic receptor screening assays
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
CN101287990B (zh) * 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
GB0708646D0 (en) * 2007-05-04 2007-06-13 Enkephala Ltd Biologically active C-terminal fragment of acetylcholinesterase
US8541185B2 (en) * 2007-09-24 2013-09-24 Technion Research & Development Foundation Limited Method of predicting responsiveness to autologous adoptive cell transfer therapy
CN101530162B (zh) * 2008-03-10 2011-11-23 北京大北农科技集团股份有限公司 一种新型蛋白饲料添加剂的制备方法

Also Published As

Publication number Publication date
BR112017020769A2 (pt) 2018-06-26
JP7327897B2 (ja) 2023-08-16
CN107531796A (zh) 2018-01-02
KR20170138414A (ko) 2017-12-15
RU2729491C2 (ru) 2020-08-07
JP2018516849A (ja) 2018-06-28
US20180051094A1 (en) 2018-02-22
AU2016240020B2 (en) 2022-02-17
AU2016240020A1 (en) 2017-11-02
MX2017012397A (es) 2018-01-26
ES2952723T3 (es) 2023-11-03
GB201505239D0 (en) 2015-05-13
CA2979972A1 (en) 2016-10-06
EP3274371B1 (en) 2023-06-07
WO2016156803A1 (en) 2016-10-06
GB2541477A (en) 2017-02-22
EP3274371A1 (en) 2018-01-31
GB201600871D0 (en) 2016-03-02
KR102626626B1 (ko) 2024-01-17
RU2017133649A3 (enExample) 2020-02-17
US10954306B2 (en) 2021-03-23
RU2017133649A (ru) 2019-04-29

Similar Documents

Publication Publication Date Title
MX392158B (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
BR112022003956A2 (pt) Anticorpos anti-cd73
JO3576B1 (ar) أجسام مضادة لـ tau واستخداماتها
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
TN2018000005A1 (en) Agents, uses and methods for the treatment of synucleinopathy
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
NZ753881A (en) Treatment of neurological diseases
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
CL2019000702A1 (es) Anticuerpos anti-gm-csf y usos de los mismos.
MX2016008968A (es) Compuestos organicos.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
WO2016150415A8 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
MY206530A (en) Methods for treating neurodegenerative disorders
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение
EA201990493A1 (ru) Антитела к гм-ксф и их применения